Navigation Links
To Stent or Not: Is That the Question?

Reporting of COURAGE study results confused the public about the need and benefits of angioplasty

PORTLAND, Ore., June 07, 2007 /PRNewswire/ -- The onslaught of anti-stent news reports over the past few months has shaped the public's view that angioplasty doesn't work and its use should decrease. Confused by the media coverage, patients have extensively questioned their cardiologists about the benefits of stenting.

"Doctor and patient dialogue is always good," said Dr. Skip Freedman, Executive Medical Director for AllMed Healthcare Management. "But there's really no controversy over the COURAGE study, because it says that nothing has really changed." COURAGE is short for the full study name Clinical Outcomes Utilizing Revascularization and Aggressive Guideline Driven Drug Evaluation.

Many consumers have misread stories in the press about stents and angioplasty as involving patients undergoing a heart attack and in dire need of either angioplasty or clot-busting medications. But this wasn't the case. The COURAGE study looked at only rather low-risk patients who are in a stable condition.

The real message is that the study reinforces long-standing clinical practice guidelines for chronic stable angina from the of Cardiology and the American Heart Association. These treatment guidelines recommend that stable angina patients start with the best medical therapy and only receive angioplasty if their chest pain continues. What the study shows is how effective medication is for fairly low-risk patients who are in a stable condition.

Has anything changed?

"The study shows that patients have a choice -- they can delay stent implantation if medication and lifestyle changes provide satisfactory freedom from symptoms," said Freedman, who is also an emergency room physician. "It says that doctors must use medication aggressively and counsel low-risk patients about the trade-offs of the two
'"/>




Page: 1 2

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
4. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
5. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Stent Not That the Question
(Date:10/8/2008)...NDRIA, Va., Oct. 8 /PRNewswire-USNewswire/ -- The ...ople die from HIV/AIDS in,sub-Saharan Africa. More...aharan Africa have already died of AIDS. The Found...g to ensure the dying and their families,find comp...e. FHSSA,s,innovative partnering initiative links ...
(Date:10/8/2008)...anolimumab Program to be Discontinued and Headcoun...ults of its Portfolio Review; Zanolimumab Program...e Number of Employee...- Genmab A/S (OMX: GEN),announced today that it is...D4(R)). In addition, as a result of a portfolio re...
(Date:10/8/2008)... France, Oct. 8 /- Vical Incorporated...nical data and new nonclinical data,demonstrating ...oadly,applicable in DNA- and protein-based infecti...ines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,S...present the data today,Wednesday, October 8, at t...
(Date:10/7/2008)...luates the efficacy of new device for detecting po...ng colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswire...nnual Scientific Meeting in Orlando (ACG 2008), re...nted results from a,multi-institutional clinical s...R) Retroscope(R), a new device that is designed to...
Breaking Medicine Technology:In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Doctors Often Fail to Spot Suicidal Patients 1926 1Doctors Often Fail to Spot Suicidal Patients 1926 2Doctors Often Fail to Spot Suicidal Patients 1926 3Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 1Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 2USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 1USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 2SalesForce4Hire Opens New Office 1920 1SalesForce4Hire Opens New Office 1920 2
...wire-FirstCall/ -- Shire plc ,the market leader i...isorder (ADHD), announced that it will present key...t the American Psychiatric,Association (APA) annua..."The upcoming clinical research to be presented at... the science of ADHD treatment,",said Eliseo Salin...
...5, 2007 - Gemin X Biotechnologies,Inc. announced t...demonstrated that its lead compound, obatoclax (GX...l Lymphoma (MCL) cell lines and,primary cells from...molecule specifically designed to inhibit all rele...ted cancer target, thus restoring,the natural cell...
Other Medicine Technology:Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 2Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 3Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 4Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 5Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 6Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 7Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...rsity of Florida, the reason obese kids do not she...playground.// The study says that bullying frequen... been picked on before, such as gym class and spor...sistant professor of psychiatry and pediatrics at ...
...forthcoming issue of the Journal of the Royal Soci...limit the amount of water //that they drink during...like headache, collapse, confusion, memory loss, v...luid accumulation in the lungs or brain. All thes...
...y (IIT) Delhi will showcase over 200 innovations r...aves collector in its annual //technological festi...st not an engineering college providing degrees to... subsequent technological innovations as well," sa...
...as simple as administering stem cell products thro... therapy can help regenerate damaged heart muscle ...the first time, reveals a new study. The distinct...travenous infusion of adult mesenchymal stem cells...
Other Medicine News:Health News:IIT Delhi To Display Its Technological Innovations In 'Open House' 2Health News:Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients 2
Introducing the new Platinum 10 concentrator. The Platinum 10 delivers the reliability, performance and value advantage you have come to expect from the Platinum line of concentrators and provides an
...table Oxygen Concentrator is the most compact, lig...than 10 lbs (4.5 kg), this unit was designed to ac...e oxygen patient., ,Operating as a pulse flow... oxygen concentrator and an oxygen conserver in on...
OCD-3000 pnuematic conserving regulator.
...7.5 liters out of your five-liter concentrators. ,...igh-flow patients! , ,In many ways, the OXYMIZER...e standard conservers, because they extend oxygen ...o saturate a patient. However, they do not requir...
Medicine Products: